CSF2 and Sepsis: Meisel et al. treated patients with sepsis (monocytic HLA-DR [mHLA-DR] <8,000 monoclonal antibodies (mAb) per cell for 2 d) GM-CSF and observed a trend toward improved disease severity and restoration of mHLA-DR expression and cytokine release [76].